Click here for slides on this topic


Percutaneous coronary intervention (PCI)

Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease (CHD).
The following content matched the glossary term: Percutaneous coronary intervention (PCI)

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Clinical Insights April 2013

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

OnsiteInsight November 2012

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

Effect of platelet inhibition with cangrelor during PCI on ischemic events

Top

Bhatt DL, Stone GW, Mahaffey KW, et al for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-1313. Percutaneous coronary intervention (PCI) with stent implantation is frequently used to reduce ischemic complications among patients with acute coronary syndrome (ACS). Despite advances in adjunctive pharmacologic therapy, thrombotic complications during PCI remain a concern.

A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease

Top

The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. N Engl J Med. 2009 Jun 7. [Epub ahead of print]. BACKGROUND: Optimal treatment for patients with both type 2 diabetes mellitus and stable ischemic heart disease has not been established.

Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction

Top

Marso SP, Miller T, Rutherford BD, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol. 2007;100(2):206-10. Epub 2007 Jun 4. Diabetes mellitus is strongly associated with increased cardiovascular morbidity and mortality in patients with ST-segment elevation myocardial infarction.

Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis

Top

Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care. 2007;30(2):384-388. Thiazolidinediones (TZDs) (rosiglitazone and pioglitazone) are a class of antidiabetes agents that have a high affinity for peroxisome proliferator-activated receptor-gamma.

Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease

Top

Breeman A, Bertrand ME, Ottervanger JP, et al. Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease. Diabetes Care. 2006;29:2003-2011. Objective: To evaluate whether in stable angina preference for coronary revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) is influenced by diabetes status and whether this has prognostic implications.



Slide Library Results

Search Results for: Percutaneous coronary intervention (PCI) Slides Found: 7
Elective Coronary Revascularization in Patients With Type 2 Diabetes
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
Platelet Inhibition During Percutaneous Coronary Intervention
CHAMPION PHOENIX: Randomization
CHAMPION PHOENIX: Ischemic Endpoints
CHAMPION PHOENIX: Baseline Characteristics